Patents for A61P 35 - Antineoplastic agents (221,099)
02/2009
02/04/2009CN100457112C Combination of medication of containing kurarinone and glycyrrhetic acid, and application
02/04/2009CN100457096C An elemene formulation and preparation method thereof
02/04/2009CN100457094C Preparing process of biodegradable capsule loading medicine and nano magnetic particle
02/04/2009CN100457093C Chinese medicinal preparation for treating liver cancer, hepatitis B cirrhosis and preventing liver fibrillation and preparation thereof
02/04/2009CN100457089C Solid liposome nanoparticles of arenobufagin and preparation method thereof
02/04/2009CN100457088C Pharmaceutical composition comprising lipids comprising polar and nonpolar moiety parts
02/04/2009CN100457086C Aseptic medicine composition
02/03/2009US7485712 A DNA sequence encoding a novel neuronal protein kinase (NPK) which phosphorylates tau proteins; for the treatment of Alzheimer's disease and cancer, diagnostic kits and in vitro diagnostic methods for the diseases
02/03/2009US7485698 Administering a polypeptide as an antitumor or anticarcinogenic agent; (giant cell) glioblastoma, gliosarcoma; anaplastic astrocytoma, oligodendroglioma, ganglioglioma or ependymoma; medulloepithelioma, ependymoblastoma, medulloblastoma, and other brain cancers; side effect reduction
02/03/2009US7485697 Nucleotide sequences coding receptor for advanced glycation endproducts (RAGE) for identifying modulators for treatment and prevention of cell proliferative and cardiovascular disorders
02/03/2009US7485664 Inhibitors of TACE
02/03/2009US7485659 Anticancer compositions, and methods of making and using the same
02/03/2009US7485647 2-aminoquinoline derivatives
02/03/2009US7485645 prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, androgenic alopecia, precocious puberty, adrenal hyperlasia and polycystic ovarian syndrome, breast cancer, endometriosis, leiomyoma and precocious puberty, estrogen dependent diseases
02/03/2009US7485639 Well tolerated; intracellularly increasing cAMP; antiasthmatics, antiinflammatories: regulation of eosinophiles activation and degranulation
02/03/2009US7485638 Pyrimidine compounds
02/03/2009US7485626 Biosynthesis of Dna ; cell proliferation; overlapping enzyme activation ; mixture of proteolytic enzyme and dipeptidyl peptidase inhibitors; autoimmune disease; antiinflammatory agents graft versus host diease
02/03/2009US7485456 Drug screening for a molecule capable of binding to NIK (nuclear factor kappa B inducing kinase); DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, isoforms, analogs, fragments and derivatives; gene expression
02/03/2009US7485422 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers
02/03/2009US7485327 For use in pharmaceuticals, dietetics and/or cosmetics; anticancer agents; for treatment of vision defects and periodontal disease
02/03/2009US7485301 Complexing, therapy, prophylaxis, medical diagnosis; antibodies, antigen binding to chemokine
02/03/2009US7485296 Using monoclonal antibodies specific for prostate stem cell antigen (PSCA) for use in diagnosis and treatment of cell proliferfative disorders; immunodiagnostics; immunotherapy
02/03/2009US7485292 Administering echovirus which recognizes integrin alpha 2 beta 1 for infectivity of the cells such that at least one of the cells are killed by the virus, wherein the abnormal cell is a cancer cell expressing alpha 2 beta 1; screening viruses
02/03/2009US7485290 bacteria belongs to the genus Megasphaera or Mitsuokella
02/03/2009CA2478302C 9-aminoacridine derivatives and process for the preparation thereof
02/03/2009CA2425164C (4-acylaminopiperidin-1-yl)acetamides as neurokinin antagonists
02/03/2009CA2420040C New phenylalanine derivatives
02/03/2009CA2323150C New porphyrins and their use
02/03/2009CA2314607C Use of ppar-.gamma. activators in dermatology
02/03/2009CA2301082C Anti-cancer compounds
02/03/2009CA2286165C A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin
02/03/2009CA2259936C Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
02/03/2009CA1341590C Human immune interferon
01/2009
01/30/2009CA2712022A1 Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026
01/30/2009CA2595671A1 Method and system for producing medicinal alcohol as a prophylatic or remedy for cancer, hiv, aids and autoimmune diseases
01/29/2009WO2009015368A2 Multikinase inhibitors for use in the treatment of cancer
01/29/2009WO2009015363A1 Zearalenone macrolide derivatives and uses of the same
01/29/2009WO2009015254A1 Triazine kinase inhibitors
01/29/2009WO2009015000A1 Pyrazole urea derivatives used as kinase inhibitors
01/29/2009WO2009014708A2 Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
01/29/2009WO2009014702A2 Cd74 for use in the treatment of cancer and liver toxicity
01/29/2009WO2009014642A1 Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
01/29/2009WO2009014450A1 Novel peptides with anti-tumor activity
01/29/2009WO2009014150A1 Benzimidazole derivative
01/29/2009WO2009014101A1 Novel sulfonated sugar derivative, and use thereof for medicinal agent
01/29/2009WO2009014100A1 p27 PROTEIN INDUCER
01/29/2009WO2009013901A1 Novel compound, method for production of the compound, pharmaceutical composition, anti-tumor agent, and use of the compound
01/29/2009WO2009013619A2 The ed-a antigen of fibrinogen is associated with the neovas culature of tumor metastases
01/29/2009WO2009013569A1 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma
01/29/2009WO2009013358A2 Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
01/29/2009WO2009013348A2 Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
01/29/2009WO2009013305A1 Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
01/29/2009WO2009013126A1 Substituted indazole derivatives active as kinase inhibitors
01/29/2009WO2009012785A2 Complexes of an emulgator and a fatty acid
01/29/2009WO2009012784A2 Methods for preparing cytotoxic complexes of emulsifier and fatty acid
01/29/2009WO2009012702A1 Use of 4-aniline quinazoline derivative for preparing medicaments
01/29/2009WO2009012647A1 Preparation methods of quinazoline derivatives and their pharmaceutical uses
01/29/2009WO2008149225A3 Anti-tumour vaccine comprising full-length wt1
01/29/2009WO2008149177A3 Marine lipid compositions and uses thereof
01/29/2009WO2008131575A3 Anti-alk antibodies suitable for treating metastatic cancers or tumors
01/29/2009WO2008109368A4 Nucleic acid compounds for inhibiting vegfr gene expression and uses thereof
01/29/2009WO2008101469A3 Pharmaceutical preparation for treating metastases
01/29/2009WO2008075201A3 Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
01/29/2009WO2008020180A3 Methods of increasing the sensitivity of cancer cells to dna damage
01/29/2009WO2008010101A9 Antagonist antibody against epha2 for the treatment of cancer
01/29/2009WO2007095749A8 Cytotoxicity mediation of cells evidencing surface expression of trop-2
01/29/2009US20090030209 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,13-dihydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-6,11-diene; antitumor compounds; using low toxic and inexpensive materials; product is readily purified; industrial production
01/29/2009US20090030088 Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
01/29/2009US20090030073 Plant-derived therapeutic agent for malignant
01/29/2009US20090030068 Antitumour Compounds
01/29/2009US20090030067 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane
01/29/2009US20090030058 Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
01/29/2009US20090030056 Novel sodium channel blockers
01/29/2009US20090030051 Inhibitors of IMPDH enzyme
01/29/2009US20090030044 Crystal of Salt of Benzimidazole Compound
01/29/2009US20090030031 Method of Preferentially Inducing the Biosynthesis of Interferon
01/29/2009US20090030030 Arylalkenyl and arylalkynyl substituted imidazoquinolines
01/29/2009US20090030028 Tetrahydroquinolines
01/29/2009US20090030027 Androgen Receptor Modulator Compounds and Methods
01/29/2009US20090030021 Quinazoline Derivatives and Therapeutic Use Thereof
01/29/2009US20090030020 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors
01/29/2009US20090030019 Purine derivatives having, in particular, anti-proliferative properties, and their biological uses
01/29/2009US20090030016 Benzimidazole poly(adp ribose)polymerase inhibitors
01/29/2009US20090030009 Heterobicyclic Carboxamides as Inhibitors for Kinases
01/29/2009US20090030005 Combinations for the treatment of cancer
01/29/2009US20090030002 Heterocyclic compounds and their uses
01/29/2009US20090029999 Synephrine derivatives useful as anti-inflammatory agents
01/29/2009US20090029997 Thiazole Derivatives and Use Thereof
01/29/2009US20090029992 Substituted pyrazole compounds
01/29/2009US20090029991 Benzamide derivatives useful as histone deacetylase inhibitors
01/29/2009US20090029988 Hydroxyalkyl Substituted Imidazoquinolines
01/29/2009US20090029986 such as 1-{(S)-2-[(5-Bromo-pyrimidin-2-ylamino)-methyl]-piperidin-1-yl}-1-quinolin-2-yl-methanone, used as human orexin receptor antagonist, for the treatment of obesity and insomnia
01/29/2009US20090029982 Protein kinase inhibitors
01/29/2009US20090029975 1,3-benzothiazinone derivative and use thereof
01/29/2009US20090029974 Tumor Treatment with Gliotoxin Derivatives
01/29/2009US20090029973 growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide
01/29/2009US20090029972 Dibenzodiazepinone Analogues, Processes for Their Production and Their Use as Pharmaceuticals
01/29/2009US20090029969 1-(2,4-dichlorophenyl)-4-methyl-5-(5-(pent-1-enyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide; cannabinoid receptor modulator; liver fibrosis, obesity, type II diabetes, atherosclerosis, analgesia, haemorrhagic shock, ischemia, liver cirrhosis, neurodegenerative diseases
01/29/2009US20090029968 Quinazoline derivatives used as inhibitors of erbb tyrosine kinase
01/29/2009US20090029965 Vasopressin V1a Antagonists